INTERCURE LTD (INCR)
IL0011063760 - Common Stock
Taking everything into account, INCR scores 3 out of 10 in our fundamental rating. INCR was compared to 195 industry peers in the Pharmaceuticals industry. INCR may be in some trouble as it scores bad on both profitability and health. INCR is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
INCR had negative earnings in the past year.
INCR had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: INCR reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: INCR reported negative operating cash flow in multiple years.
1.2 Ratios
The Return On Assets of INCR (-7.88%) is better than 74.19% of its industry peers.
The Return On Equity of INCR (-13.61%) is better than 74.73% of its industry peers.
With an excellent Return On Invested Capital value of 4.83%, INCR belongs to the best of the industry, outperforming 81.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.88% | ||
| ROE | -13.61% | ||
| ROIC | 4.83% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Operating Margin value of 9.64%, INCR belongs to the best of the industry, outperforming 81.72% of the companies in the same industry.
With a Gross Margin value of 30.47%, INCR perfoms like the industry average, outperforming 53.76% of the companies in the same industry.
INCR's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.64% | ||
| PM (TTM) | N/A | ||
| GM | 30.47% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.28%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so INCR is destroying value.
INCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
INCR has an Altman-Z score of 1.06. This is a bad value and indicates that INCR is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INCR (1.06) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.23 indicates that INCR is not too dependend on debt financing.
INCR has a Debt to Equity ratio (0.23) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.06 |
ROIC/WACC0.46
WACC10.48%
2.3 Liquidity
A Current Ratio of 1.85 indicates that INCR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.85, INCR is doing worse than 61.83% of the companies in the same industry.
INCR has a Quick Ratio of 1.39. This is a normal value and indicates that INCR is financially healthy and should not expect problems in meeting its short term obligations.
INCR's Quick ratio of 1.39 is on the low side compared to the rest of the industry. INCR is outperformed by 69.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.39 |
3. Growth
3.1 Past
INCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.58%.
The Revenue has decreased by -8.52% in the past year.
Measured over the past years, INCR shows a very strong growth in Revenue. The Revenue has been growing by 76.16% on average per year.
EPS 1Y (TTM)-237.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-821.9%
Revenue 1Y (TTM)-8.52%
Revenue growth 3Y76.16%
Revenue growth 5YN/A
Sales Q2Q%236.68%
3.2 Future
The Earnings Per Share is expected to grow by 80.53% on average over the next years. This is a very strong growth
Based on estimates for the next years, INCR will show a quite strong growth in Revenue. The Revenue will grow by 14.31% on average per year.
EPS Next Y90.7%
EPS Next 2Y83%
EPS Next 3Y80.53%
EPS Next 5YN/A
Revenue Next Year-24.35%
Revenue Next 2Y2.66%
Revenue Next 3Y14.31%
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for INCR. In the last year negative earnings were reported.
Also next year INCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, INCR is valued cheaply inside the industry as 90.86% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.8 |
4.3 Compensation for Growth
INCR's earnings are expected to grow with 80.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83%
EPS Next 3Y80.53%
5. Dividend
5.1 Amount
No dividends for INCR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTERCURE LTD
NASDAQ:INCR (1/14/2025, 8:00:02 PM)
Premarket: 1.73 +0.04 (+2.37%)1.69
+0.06 (+3.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners12.95%
Inst Owner Change0%
Ins Owners39.6%
Ins Owner Change0%
Market Cap77.35M
Analysts82.86
Price TargetN/A
Short Float %0.17%
Short Ratio0.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.79 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.62 | ||
| P/tB | 1.2 | ||
| EV/EBITDA | 7.8 |
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS2.14
BVpS2.74
TBVpS1.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.88% | ||
| ROE | -13.61% | ||
| ROCE | 6.11% | ||
| ROIC | 4.83% | ||
| ROICexc | 5.9% | ||
| ROICexgc | 11.37% | ||
| OM | 9.64% | ||
| PM (TTM) | N/A | ||
| GM | 30.47% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.28%
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 19.89% | ||
| Cap/Sales | 0.74% | ||
| Interest Coverage | 1.64 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.39 | ||
| Altman-Z | 1.06 |
F-Score3
WACC10.48%
ROIC/WACC0.46
Cap/Depr(3y)126.13%
Cap/Depr(5y)882.8%
Cap/Sales(3y)4.07%
Cap/Sales(5y)71.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-821.9%
EPS Next Y90.7%
EPS Next 2Y83%
EPS Next 3Y80.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.52%
Revenue growth 3Y76.16%
Revenue growth 5YN/A
Sales Q2Q%236.68%
Revenue Next Year-24.35%
Revenue Next 2Y2.66%
Revenue Next 3Y14.31%
Revenue Next 5YN/A
EBIT growth 1Y-45.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year782.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-278.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-204.61%
OCF growth 3YN/A
OCF growth 5YN/A